Overview
Multi-strain probiotic supplementation with L. acidophilus, B. longum, and B. bifidum has shown promise in slowing CKD progression through anti-inflammatory mechanisms, though its effect on uremic toxins remains unconfirmed.
Mechanism
- Restores commensal populations depleted by the uremic milieu
- Reduces bacterial translocation and endotoxemia by improving gut barrier integrity
- Decreases systemic inflammatory markers (IL-6, IL-18, TNF-alpha) that drive renal fibrosis
Clinical Evidence
- eGFR preservation: Decline slowed from -0.54 to 0.00 ml/min/month in the supplemented group
- Endotoxin reduction: Significant decrease in circulating endotoxin levels
- Inflammatory markers: IL-6, IL-18, and TNF-alpha all decreased
Important Limitation
A meta-analysis of 21 RCTs found that probiotics did NOT significantly reduce indoxyl sulfate or p-cresyl sulfate levels. The renal benefit may operate through anti-inflammatory pathways rather than uremic toxin reduction.